Al Musella`s ASCO Highlights Part 2
Some more of what I feel are the most important reports from ASCO 2020!
Posted on: 05/29/2020
Al Musella's ASCO Highlights Part 2
- Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: A multicenter phase II study. BNCT is a form of radiation therapy. They are reporting pretty good results for recurrent GBM - 18 months.
- SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.
This is an experimental vaccine. They report early result that look very good. PFS of 13.9 months - with Survival at 12 months of 93% for methylated MGMT and 78% for unmethylated MGMT.
- Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival. This vaccine is showing promising results - including a few complete responses which are pretty rare in recurrent GBM! They report on results on 5 compassionate use patients - so it might be easy to get.
- Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. Another promising vaccine with one complete response and a few partial responses. Median overall survival was 12 month which is good for recurrent GBM!
Click HERE to return to brain tumor news headlines